$10,000 in NuScale at Its 52-Week High Is Worth About $1,650 Today

NuScale Power shares collapsed from about $57.42 (52-week high) to roughly $9.50, a loss of ~5/6 in ~10 months. Q2 revenue fell to just $75,000 versus $8.1M a year earlier, with the weighted share count rising to ~365M from ~133M. The company also filed Aug. 11 to sell up to $750M more stock, while key order catalysts (TVA and Romania’s SMR project conditions) remain pending rather than contracted.

Analysis

This is no longer an industrial execution story; it is a financing treadmill with an embedded call option on a contract that has not been won yet. When a company’s equity value remains billions while realized revenue is effectively immaterial, the market is paying for a future backlog conversion that can be postponed repeatedly, and each delay raises the cost of capital because equity issuance becomes the only credible funding source. The immediate loser is the common shareholder: dilution is doing more work than operations, so per-share upside now depends on non-dilutive project finance or a signed PPA, not on technology milestones.

The second-order effect is that every month without a binding customer makes the certified-design narrative less powerful and more like a sunk-cost argument. That tends to compress the multiple not just on SMR but on the broader pre-revenue advanced-nuclear basket, because investors start discounting “regulatory approval” as necessary but not sufficient; what matters is bankability, EPC execution, and customer credit quality. If the market begins to view the name as a repeat equity issuer rather than a utility infrastructure developer, the stock trades with biotech-style event risk, not infrastructure scarcity value.

Near term, the catalyst path is binary: a signed TVA-style agreement or Romania close could trigger a sharp squeeze, but absent that, the next equity raise is the more probable headline. The contrarian view is that the washout may be overdone if even one credible utility contract lands, because the option value on first-of-kind deployment is real; however, that upside is only valid if management can stop funding growth by selling stock. Falsification for the bearish view is straightforward: binding orders, visible backlog conversion, and a slowdown in share count growth over the next 1-2 quarters.

Key Decisions for Investors

• Short SMR on rallies above ~$10.50 with a 1-3 month horizon; target a move back toward the high single digits as dilution and contract slippage reprice the equity. Invalidate the short only on a binding utility contract or materially non-dilutive financing.
• Buy 3-6 month SMR put spreads rather than naked puts to express the financing-overhang view; this limits theta burn if the stock stays range-bound while preserving convexity on a failed PPA or another equity sale.
• Use any headline-driven spike on TVA/Romania speculation to reduce exposure rather than add; the risk/reward worsens quickly if the market starts paying for optionality before backlog is contractually locked.
• Watch for a quarter with no meaningful backlog conversion and another uptick in share count; if that pattern persists, treat SMR as a funded-R&D equity story, not a commercial project, and avoid averaging down.